COVID-19 Pandemic Provides Opportunities to Innovate With Oral Oncolytics, Medically Integrated Dispensing

Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.

In an interview with Pharmacy Times, Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.

In the interview, Stutz and Alwardt discussed the necessity for close monitoring when patients receive oral oncolytics, potential concerns about adherence, and how telemedicine enabled this care and monitoring. Stutz and Alwardt also co-authored an article on the subject, which will be featured in the October issue of Directions in Oncology Pharmacy.

Related Videos
Patient with cancer receiving an infusion | Image credit: RFBSIP - stock.adobe.com
Burnout illustration | Image credit: Vikky Mir - stock.adobe.com
Stack of files and gavel | Image credit: BillionPhotos.com - stock.adobe.com
Cancer patient with IV | Image credit: Monkey Business - stock.adobe.com
Capitol Building | Image credit: lazyllama - stock.adobe.com
Smiling Asian female pharmacist working in chemist shop or pharmacy | Image Credit: Atstock Productions - stock.adobe.com
sofiko14 / stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.